| Revenue growth | 47% QoQ recovery in Q4; 2% YoY decline for full FY26. |
|---|---|
| Margins | Q4 EBITDA margin expanded 1,550 bps sequentially; targeting 40% by FY28. |
| Order book | Current capacity fully committed; capacity reservation via upfront fees. |
| Demand visibility | Strong visibility for GLPs; demand exceeding current supply capacities. |
| Management confidence | High; reiterating ambitious FY28 long-term revenue and margin targets. |
Growth
Q4 revenue at ₹4,282M (+47% QoQ); FY26 revenue ₹14,216M (-2% YoY). Q4 EBITDA at ₹919M.
Outlook
Reiterated FY28 guidance: US$400M organic revenue with 40% EBITDA margins. US$100M capex for capacity expansion underway.
Risks
Regulatory changes in Labor Code; delayed approvals in Canada previously impacted H2; potential supply-demand gaps in emerging markets.
Earnings Call filed with BSE, NSE: ONESOURCE. Summary written with AI assistance from the document.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,602.60
- Market cap
- ₹18,377 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -378.0×Sector 50.4×
- Promoter holding
- 30.48%+0.00% QoQ
- FII holding
- 19.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Employee Stock Options
Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.
- Value
- ₹0.03 Cr
OneSource Specialty Pharma Management Change
Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.
OneSource Specialty Pharma Other Announcement
OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.